Azithromycin ophthalmic solution, 1%
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posterior Blepharoconjunctivitis
Conditions
Posterior Blepharoconjunctivitis
Trial Timeline
Nov 1, 2010 → Aug 1, 2011
NCT ID
NCT01220258About Azithromycin ophthalmic solution, 1%
Azithromycin ophthalmic solution, 1% is a phase 2 stage product being developed by Merck for Posterior Blepharoconjunctivitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01220258. Target conditions include Posterior Blepharoconjunctivitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01269658 | Phase 2 | Terminated |
| NCT01220258 | Phase 2 | Terminated |
| NCT01105624 | Approved | Completed |
| NCT01014078 | Approved | Completed |
| NCT00894530 | Phase 2 | Completed |
| NCT00892970 | Phase 2 | Completed |
Competing Products
10 competing products in Posterior Blepharoconjunctivitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| Adalimumab | AbbVie | Approved | 85 |
| Esomeprazole + Placebo | AstraZeneca | Approved | 85 |
| Sugammadex Injection [Bridion] + Placebo | Merck | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| REGN7041 | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 49 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Sham Injection + FAI Insert | EyePoint Pharmaceuticals | Phase 3 | 72 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 44 |